• Chiara Briani, Andreas A Argyriou, Cristina Izquierdo, Roser Velasco, Marta Campagnolo, Paola Alberti, Barbara Frigeni, Mario Cacciavillani, Francesca Bergamo, Diego Cortinovis, Marina Cazzaniga, Jordi Bruna, Guido Cavaletti, and Haralabos P Kalofonos.
• Department of Neurosciences, Sciences NPSRR, University of Padova, Padova, Italy.
• J. Peripher. Nerv. Syst. 2014 Dec 1; 19 (4): 299-306.

AbstractThis prospective study sought to identify the potential reversibility of oxaliplatin-induced peripheral neuropathy (OXAIPN) by following-up its long-term course 2 years after discontinuation of oxaliplatin (OXA)-based chemotherapy. Participants were 91 colorectal cancer patients treated with OXA-based chemotherapy. Neurological assessment, clinical Total Neuropathy Score© (TNSc©) and nerve conduction studies were performed at baseline (T0), the end of chemotherapy (T1) and 2 years (T2) after discontinuation of chemotherapy. A total of 73 of 91 (80%) patients experienced OXAIPN at T1. At a median follow-up of 25 months, persistence of chronic OXAIPN was present in 61 of 73 patients (84%) and complete resolution was present in 12 patients (17%). Longitudinal comparison of TNSc© values between T1 and T2 revealed that the overall severity of OXAIPN in those 61 patients significantly decreased over time. Median TNSc© values were nine (range: 2-15) at T1 vs. four (range: 2-12) at T2 (P < 0.001). Likewise, sensory nerve conduction measures at T2 significantly improved in all sensory nerves tested, compared with T1. Severity of OXAIPN at T2 was significantly associated (P < 0.001) with high severity of OXAIPN at T1. In conclusion, persistence of OXAIPN beyond 2 years after finishing chemotherapy is common. Clinical and neurophysiological improvement is observed, although recovery is often incomplete.© 2015 Peripheral Nerve Society.

35 keywords...

hide…